Positive result of intraarterial thrombolysis in acute ischemic stroke

Original title: A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. MR CLEAN Investigators. Reference: O.A. Berkhemer et al. N Engl J Med 2015;372:11-20.

In patients undergoing acute ischemic stroke caused by a proximal intracranial artery occlusion, intraarterial endovascular treatment is effective; however, there is no evidence of clinical or functional benefits. 

This study randomized patients undergoing stroke caused by proximal occlusion of an anterior artery (confirmed by images) to intraarterial treatment plus standard treatment vs. standard treatment only. Patients were eligible if found within 6 hrs of symptom onset. 

Primary endpoint was the modified Rankin scale score at 90 days. This scale measure the functional sequel of events from cero (asymptomatic) to six (death). 

500 patients from 16 centers in The Netherlands were enrolled (233 to intraarterial treatment and 267 to standard treatment). From the total number of patients, 445 (89%) had received intravenous perfusion of alteplase prior to randomization. Retrievable stents were used in 190 of the 233 patients (81.5%) randomized to intraarterial treatment.

There was an absolute difference of 13.5 percentage points (CI 95%, 5.9 to 21.2) in the modified Rankin scale in favor of intervention (32.6% vs 19.1%). There was no significant difference in mortality or symptomatic intracranial bleeding rate.

Conclusion

In patients undergoing acute ischemic stroke caused by proximal occlusion of an anterior artery, intraarterial treatment within 6 hrs of symptom onset is safe and effective.

Editorial Comment

Similar previous studies have not shown benefits and found it difficult to enroll patients, mainly due to delayed consultation after symptoms onset. Even though study findings are positive, in 9%  of patients receiving intraarterial treatment thrombus material spread to a new territory and 13% also received carotid PCI at the time. This complexity should be taken into account when interpreting study outcomes.

SOLACI

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...